This article is more than 5 years old. Information may no longer be current.
Prostaglandin analogues yield similar safety, efficacy in different racial groups
J Glaucoma. 2010;19(7):460-467.
Click Here to Manage Email Alerts
Three prostaglandin analogues proved similarly safe and effective among different racial groups, a study found.
"All three prostaglandin/amide drugs are highly effective at lowering IOP," the study authors said. "No differences in effect between the drugs or between members of different racial groups were detected, although the study sample size was too small to be certain to detect differences, if they existed."
The PRESSURE (Prostaglandin efficacy and safety study undertaken by race) Study, a prospective, randomized investigator-masked multicenter study, included 83 patients with a mean age of 61.5 years. Patients were assigned to one of two general racial groups: white or other. The sample size was too small to allow adequate analysis of differences between subgroups.
Patients with open-angle glaucoma or elevated IOP following a washout period were randomized to receive Xalatan (latanoprost, Pfizer), Travatan (travoprost, Alcon) or Lumigan (bimatoprost, Allergan). Specifically, 30 patients received latanoprost, 26 patients received travoprost and 27 patients received bimatoprost.
IOP and drug side effects were evaluated at 2, 6, 12 and 24 weeks.
Study data showed statistically significant decreases in IOP from baseline to 12 weeks and from baseline to 24 weeks (both P < .0001).
The IOP-lowering effect of the three drugs was similar. Results showed no differences in treatment effect between the two groups.